Search Insights

Insights

87 Insights found for Intellectual Property > Hatch-Waxman and Biosimilars
TITLE
Event

Inherent Obviousness: A Case Study on a Less Known but Effective Defense

9th Annual Pharma IPR Conference 2020

Location:
Mumbai, India
Event
Event

Trends in Hatch-Waxman Litigation

IPR Connexion

Location:
webinar
News Release

Schiff Hardin Named One of 10 Firms “GCs Love for Pharma Work”

BTI’s Power Ranking 2016 recognized Schiff Hardin in its top category—Clientopia®—for the firm’s work on behalf of the pharmaceutical industry.

News Release

Clients Recognize Schiff Hardin as a Top Firm in Pharma Two Years in a Row

For the second consecutive year, Schiff Hardin has been recognized as a top “Clientopia” law firm in the BTI Industry Power Rankings 2017.

News Release

IP Practice Group Leader Recognized Among World’s Leading Patent Professionals

Schiff Hardin Intellectual Property Practice Group Co-Leader Imron Aly has been recognized as a leading patent litigator in Illinois in the 2017 IAM Patent 1000 guide, based on outstanding feedback from peers and clients.

In The News
News Release

Schiff Hardin Expands Global Generic Pharmaceuticals Practice With Addition of Kevin M. Nelson in Chicago

Schiff Hardin LLP today announced the addition of Kevin M. Nelson as a partner in its rapidly growing Intellectual Property Group.

News Release

Schiff Hardin Recognized as a Top Hatch-Waxman Defense Firm

Schiff Hardin LLP has been recognized as one of the top law firms defending Abbreviated New Drug Application (ANDA) litigation in the 2017 Hatch-Waxman/ANDA Litigation Report compiled by legal data analytics firm Lex Machina.

News Release

Aly and Patel Named 2018 Life Sciences Stars

Imron Aly and Sailesh Patel have been named Life Sciences Stars in the Hatch-Waxman Patent Litigation Practice Area by LMG Life Sciences in its 2018 guide.

In The News
In The News
In The News
In The News
In The News
In The News
In The News
In The News

Patel Featured on BPCIA Litigation to Watch

The Center for Biosimilars

News Release

Schiff Hardin Secures Patent Infringement Win

Schiff Hardin successfully secured a favorable outcome for our client, Fresenius Kabi USA LLC, in a patent-infringement suit filed by Hospira Inc., which paves the way for Fresenius to market a new generic drug.

In The News
News Release

Aly and Patel Named 2019 Life Sciences Stars

Intellectual Property Practice Group Co-Leaders Imron Aly and Sailesh Patel were named Life Sciences Stars in the Hatch-Waxman Patent Litigation Practice Area by LMG Life Sciences in its 2019 guide.

In The News
News Release

Aly Joins Center for Biosimilars Advisory Board

Intellectual Property Practice Group Co-Leader Imron Aly has joined the advisory board for the Center for Biosimilars, an online resource for emerging pharmaceutical biotechnology that discusses the current landscape for advanced health care management with top industry thought leaders.

In The News
In The News

Patel Featured on Patent Hurdles Faced by Biosimilars to Get to Market

Biosimilars Patent and Antitrust Perspectives Virtual Panel

News Release

Aly Named Among Crain’s Chicago Notable Minorities in Law

Schiff Hardin LLP is pleased to announce that Intellectual Property Group Co-Leader Imron Aly has been named to Crain’s Chicago Business’ Notable Minorities in Accounting, Consulting & Law list for 2020.

News Release

Aly, Nelson, and Patel Named 2020 Life Sciences Stars

Intellectual Property Practice Group Co-Leaders Imron Aly and Sailesh Patel and partner Kevin Nelson were named Life Sciences Stars in the Hatch-Waxman Patent Litigation Practice Area by LMG Life Sciences in its 2020 guide.

In The News
In The News
In The News
News Release

Firm and Four Attorneys ranked in the 2020 IAM Patent 1000

Schiff Hardin LLP is proud to announce that the firm and four of its attorneys have been ranked in the ninth edition of IAM Patent 1000: The World’s Leading Patent Professionals, a guide that identifies top patent professionals based on 1,800 interviews with private practice and in-house professionals.

News Release

Intellectual Property Group and Co-Leader Aly Honored for Hatch-Waxman Litigation

Schiff Hardin LLP is pleased to announce that the firm’s Intellectual Property Practice Group has received the Impact Case of the Year award in 2020 by LMG Life Sciences for our ground-breaking patent-infringement victory in Fresenius Kabi v. Hospira.

In The News
News Release

Firm and Four Attorneys Ranked in the 2021 IAM Patent 1000

Schiff Hardin LLP is proud to announce that the firm and four of its attorneys have been ranked in the 2021 edition of IAM Patent 1000: The World’s Leading Patent Professionals, a guide that identifies top patent professionals based on 1,800 interviews with private practice and in-house professionals.

News Release

LMG Life Sciences Recognizes the Firm and 3 Partners in 2021

Schiff Hardin has been ranked “Recommended” by LMG Life Sciences in the Hatch-Waxman Patent Litigation (Generic) category of its 2021 guide.

In The News
News Release

The Legal 500 US 2021 Ranks Four Practices, 12 Attorneys

Schiff Hardin LLP is pleased to announce that four of the firm’s practice groups have been recognized in The Legal 500 United States 2021 guide, which provides a nationwide analysis of law firms that provide cutting-edge and innovative advice.

Newsletter
Trending Legal Issue
Alert

Pharma team scores rare preliminary injunction

Schiff Hardin’s pharma and life sciences patent litigation team, lead by partner Imron T. Aly, recently secured a preliminary injunction in federal court.

Alert

6 Ways to Strengthen Your Boilerplate NDAs

Many companies rely on boilerplate confidentiality provisions to protect their trade secrets and other sensitive business information.

Alert

Pharma Giants in Antitrust Pricing Lawsuit over Biosimilars

Pfizer sued Johnson & Johnson (J&J) in federal court in Pennsylvania last week, alleging anticompetitive discounts and other actions to prevent competition with J&J’s biologic Remicade.

Alert

Supreme Court Delivers Big Patent-Dance-Limiting Win for Biosimilars

Earlier this week, the U.S. Supreme Court unanimously held, in its first case interpreting the Biologics Price Competition and Innovation Act of 2009, Sandoz Inc. v. Amgen Inc.

In The News
Alert

Four Key Issues to Watch in the U.S. Biosimilars Industry

Like generic drugs in the 1980s, biosimilars today face a number of regulatory, legal, scientific, and public perception obstacles to continued growth.

Blog Post

Generically Speaking: Liability is Limited in Failure to Warn Claims

Schiff Hardin Product Liability & Mass Torts Blog

Article
Article
Alert

U.S. Pharmaceutical and Biologics Industries Could See Steep Potential Consequences from Texas Judge’s ACA Decision

In the quick pound of a gavel, the entire U.S. pharmaceutical and biologics industries were thrown into doubt after Judge Reed O’Connor of the United States District Court for the Northern District of Texas found the individual mandate of the Affordable Care Act (ACA) – and therefore the entire act – unconstitutional.

Alert

How Pharmaceutical Companies Can Navigate FDA During Shutdown

As the government shutdown stretches on, pharmaceutical companies must manage the partial shutdown of the U.S. Food and Drug Administration (FDA).

Article

What if Pfizer Could Donate Data to NIH? One Proposal to Promote Public Good

Pfizer’s recent decision not to disclose data about Enbrel’s potential to treat Alzheimer’s disease has caused much debate about drugmakers’ obligations to the public.

Alert

FDA Rule Shifting Drugs to New Approval Pathway May Cause Continued Generics Delays

The U.S. Food and Drug Administration (FDA) issued a final rule last week that broadened the scope of the Biologics Price Competition and Innovation Act (BPCIA) to include large proteins, even those that could have been previously governed by the Hatch-Waxman Act.

Alert

If Successful, Teva Suit Could Decrease Generic Competition

Teva Pharmaceuticals filed suit against the United States Food and Drug Administration (FDA) alleging that its glatiramer (Copaxone) falls under the revised definition of a “biological product” and should be transitioned to the system established by the Biologics Price Competition and Innovation Act of 2009 (BPCIA).

Article